[HTML][HTML] Real-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors

H Mehta, A Tufail, V Daien, AY Lee, V Nguyen… - Progress in retinal and …, 2018 - Elsevier
Clinical trials identified intravitreal vascular endothelial growth factor inhibitors (anti-VEGF
agents) have the potential to stabilise or even improve visual acuity outcomes in …

Advances in aptamer screening technologies

J Yan, H Xiong, S Cai, N Wen, Q He, Y Liu, D Peng… - Talanta, 2019 - Elsevier
Systematic evolution of ligands by exponential enrichment (SELEX) is a well-established
technology for the screening of aptamers binding to various targets with relatively high …

Mechanisms of bone pain: Progress in research from bench to bedside

G Zhen, Y Fu, C Zhang, NC Ford, X Wu, Q Wu, D Yan… - Bone Research, 2022 - nature.com
The field of research on pain originating from various bone diseases is expanding rapidly,
with new mechanisms and targets asserting both peripheral and central sites of action. The …

Brolucizumab in neovascular age-related macular degeneration–Indian real-world experience: the BRAILLE study

D Chakraborty, A Maiti, JU Sheth, S Boral… - Clinical …, 2021 - Taylor & Francis
Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab
injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under …

French medical-administrative database for epidemiology and safety in ophthalmology (EPISAFE): the EPISAFE collaboration program in cataract surgery

V Daien, JF Korobelnik, C Delcourt… - Ophthalmic …, 2017 - karger.com
Medical-administrative databases are an important source of big data to assess the
epidemiology of diseases and interventions, compare drugs, and investigate rare adverse …

The use of real-world evidence for evaluating anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration

J Talks, V Daien, RP Finger, B Eldem, T Sakamoto… - Survey of …, 2019 - Elsevier
Randomized controlled trials are the gold standard in medical research, providing evidence
of the efficacy of a treatment in well-defined patient populations. By contrast, real-world …

[HTML][HTML] Brolucizumab in Neovascular Age-Related Macular Degeneration–Indian Real-World Experience: The BRAILLE Study–Fifty-Two-Week Outcomes

D Chakraborty, A Maiti, JU Sheth… - Clinical …, 2022 - ncbi.nlm.nih.gov
Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World
Experience: The BRAILLE Study – Fifty-Two-Week Outcomes - PMC Back to Top Skip to main …

Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis

X Xie, C Lian, Z Zhang, M Feng, W Wang… - Frontiers in …, 2023 - frontiersin.org
Purpose This meta-analysis compared the long-term (12 months or 24 months) efficacy and
safety of intravitreal aflibercept injection (IAI) for diabetic macular edema (DME) and …

[HTML][HTML] Human Antigen R-mediated modulation of Transforming Growth Factor Beta 1 expression in retinal pathological milieu

SP Mohan, H Nagarajan, U Vetrivel… - … and Biophysics Reports, 2024 - Elsevier
The fate and stability of messenger RNA (mRNA), from transcription to degradation is
regulated by a dynamic shuttle of epigenetic modifications and RNA binding proteins in …

Real-world safety outcomes of intravitreal ranibizumab biosimilar (razumab) therapy for chorioretinal diseases

D Chakraborty, MW Stewart, JU Sheth… - Ophthalmology and …, 2021 - Springer
Introduction To assess the safety profile of the intravitreal ranibizumab biosimilar molecule,
Razumab®(Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real …